Appili Therapeutics Inc. (APLI.TO)
| Previous Close | 0.0400 |
| Open | 0.0500 |
| Bid | 0.0450 x N/A |
| Ask | 0.0500 x N/A |
| Day's Range | 0.0500 - 0.0550 |
| 52 Week Range | 0.0350 - 0.1800 |
| Volume | |
| Avg. Volume | 224,040 |
| Market Cap | 3.92M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1990 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.38 |
- Business Wire
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
HALIFAX, Nova Scotia, November 14, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense ("DOD"), via the Joint Science and Technology Office of the Defense Threat Reduction Agency ("DTRA") in partnership with the U.S. Air Force Academy ("USAFA"), will provide at least US$14 million in funding over two years to fund th
- Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia, November 10, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.
- Business Wire
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, September 22, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.
